TOP TEN REASONS I'M LONG ON $USRM RIGHT NOW. #1. If approved for RMAT (Regenerative Medicine Advanced Therapy Designation), $USRM's #1 product candidate = Myocell - will be allowed to generate revenues in the United States. #2 MyoCell therapy is projected to cost: "$35,000 to $45,000 range" per patient.
If/When approved, USRM can apply for a new technology add-on payment. If the application is accepted, Medicare would pay a marginal cost factor of 50% of the costs for the new technology in excess of the full DRG payment. Considering ICDs (implantable cardioverter defibrillator) cost $23,000 or more and have to be replaced every four to seven years, Myocell therapy will be a primary candidate for additional reimbursement. Myocell could be highly sought after by Health Insurance Companies. #3 Northstar Biotech Group LLC
, a consortium of $USRM insiders, is holding intellectual property related to Myocell, and also holding many common shares of $USRM. "the Company granted Northstar a perpetual license on products as described for resale, relicensing and commercialization outside the United States. In connection with the granted license, Northstar shall pay the Company a royalty of up to 8% on revenues generated. Our CEO, Mike Tomas, and CSO Kristen Comella just recently became 5% owners/members of Northstar. "Northstar also Agrees to 10% of international sales from $USRM" https://www.google.es/patents/US20020124855?dq=assignee+northstar+biotech+group+llc&hl=en&sa=X&ved=0ahUKEwjSpZKG2-vSAhXC6oMKHcyeCfMQ6AEIKDAC #4 I am confident former CEO Howard L., is still involved in this
, Howard laid the ground work for all of this to be possible. Although he appears to be keeping quiet about it for now.. He has many reasons to make this a success (from his website): "Note – Bioheart (USRM) will receive royalties and milestone payments from MyoStim Pacers, BioPace and BioLeonhardt." Bioleohardt is a company projected to be worth 3 Billion according to him: http://www.bioleonhardt.com/about/ #5 Besides Patents held by Northstar, Myocell is protected by:
- U.S. Drug Price Competition and Patent Term Restoration Act of 1984
-The Patient Protection and Affordable Care Act, or Affordable Care Act, signed into law on March 23, 2010, included a subtitle called the Biologics Price Competition and Innovation Act of 2009
It would take many many years for the competition to prove "safety and efficacy" in a similar therapy that attempted to replicate Myocell. #6 The 21st Century Cures Act, & the Recent Changes within our Govt.
The 21st Century Cures Act, paving the way for a fast and reasonable way to let regenerative therapies get to those patients who need it! The new Presiden*t, Donal*d Trum*p and his record of showing support for people with rare diseases. Also. The New FDA Commissioner: Scott Gottlieb and his willingness to "slash the restraints of the FDA" #7 $USRM's Leadership:
Kristin Comella, and her vast knowledge and experience in thousands of stem cell procedures, being a leading scientist and world renowned expert in regenerative medicine. She is a smart and I trust her to represent us. She has fought for us in front of the FDA since the Cures act was first in front of congress, and she will continue to fight for patients who need stem cell treatment.
Mike Tomas, His leadership over the last 6 months, has alleviated $USRM of their lawsuit with Northstar, and has positioned the company to obtain up to 7.5million dollars of non-dilutive financing, while not adding any more convertible notes. He has arranged agreements with partners in order to expand our clinical operations into 10 other "Metropolitan Areas" in the United States.
William P. Murphy. Our Chairman of the board. besides that he started Cordis Corp(sold for 1.9 Billion to J&J), Cordis currently is a key factor in Myocell being able to effectively treat patients with their NOGA heart mapping and Catheter systems. A pioneer of medicine, Dr. Murphy is an ally and investor that truly believes in his work that he has done with bioheart aka USRM. His connections to big pharma may ultimately prove most valuable. #8 Buyout rumors from the pacer filings related to Northstar.
you can read about that here: http://investorshub.advfn.com/boards/read_msg.aspx?message_id=129567646 #9 Heart Failure is the LEADING COST OF HEALTHCARE. WORLDWIDE.
31 BILLION DOLLARS IS SPENT ON TREATING PATIENTS WITH CHRONIC HEART FAILURE. THERE IS CURRENTLY NO THERAPY COMMERCIALLY AVAILABLE IN THE UNITED STATES THAT IS ABLE TO REGENERATE SCARRED HEART TISSUE- AFTER A HEART ATTACK! #10 USRM is HIGHLY UNDERVALUED AT THIS PRICE.
Compared to others in the Stem Cell Sector, being convertible free, and on the cutting edge of receiving the United States first RMAT designation for Stem Cells directly injected into the heart, USRM could ultimately become a company worth Billions of Dollars with a BLOCKBUSTER Stem Cell Therapy!
BRAVE LONGS! This company has been through it's up's and downs, but we are here. In the final hours of FDA decision. Every day,- the company gets better positioned than ever before. Will the FDA give way to the dark forces and drug companies hellbent on holding back the Future of Medicine? Or will the 21st Century Cures Act, the resolve of the New Administration, and new FDA commissioner, -unleash the Miracles of Cell Therapy upon the World!?
I'm betting on the latter.
LONG on $USRM!